Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.91 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340944 | 0.96 | GPR119 (0.85) | GPR119HRH3ALK | |
| SCHEMBL2573353 | 0.95 | GPR119 (1.00) | GPR119HRH3ALK | |
| SCHEMBL2573355 | 0.95 | GPR119 (1.00) | GPR119HRH3ALK | |
| SCHEMBL24117836 | 0.93 | GPR119 (0.79) | GPR119HRH3ALK | |
| SCHEMBL5091205 | 0.93 | GPR119 (0.79) | GPR119HRH3ALK | |
| SCHEMBL31632594 | 0.93 | GPR119 (0.79) | GPR119HRH3ALK | |
| SCHEMBL21825090 | 0.87 | GPR119 (0.71) | GPR119HRH3ALK | |
| SCHEMBL3605978 | 0.86 | GPR119 (0.69) | GPR119ALK | |
| SCHEMBL5687614 | 0.84 | GPR119 (0.67) | GPR119HRH3ALK | |
| SCHEMBL14087517 | 0.84 | GPR119 (0.67) | GPR119HRH3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | DIGMBIO. INC. (KR) | 2023-01-26 | — | — | US | disclosed |
| CN-114929673-A | Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for preventing or treating poly (ADP-ribose) polymerase 1(PARP-1) -related diseases comprising the same as active ingredient | 多临生物株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022130352-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2022-06-23 | — | — | WO | disclosed |
| US-20210392895-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LIMITED (IN) | 2021-12-23 | — | — | US | disclosed |
| US-20210392895-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LIMITED (IN) | 2021-12-23 | — | — | US | disclosed |
| EP-3860992-A1 | NOVEL OXADIAZOLES | PI Industries Ltd. (IN) | 2021-08-11 | — | — | EP | disclosed |
| CN-113195483-A | Novel oxadiazole compound | PI工业有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20050245571-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| EP-1554260-A1 | ARYLOXYALKYLAMINE DERIVATIVES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005061442-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1437351-A1 | AMINE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004037800-A1 | ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210392895-A1 | NOVEL OXADIAZOLES | OXA1L, CYP1B1, CYP1A1 | GPR119 741/4885HRH3 958/4885ALK 3531/4885 |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | GPR119 4303/4885HRH3 3716/4885ALK 3365/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | GPR119 4817/4885HRH3 2698/4885ALK 4579/4885 |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | PARP1, PARP2, PARP11 | GPR119 2726/4885HRH3 3708/4885ALK 4637/4885 |
| US-20050245571-A1 | Amine derivative | NPY1R, SSTR1, SSTR5 | GPR119 28/4885HRH3 58/4885ALK 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.